CheckMate 817: First-Line Nivolumab plus Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC

被引:40
作者
Barlesi, F. [1 ,2 ,3 ]
Audigier-Valette, C. [4 ]
Felip, E. [5 ]
Ciuleanu, T. [6 ,7 ]
Jao, K. [8 ]
Rijavec, E. [9 ]
Urban, L. [10 ,11 ]
Aucoin, J. [12 ]
Zannori, C. [13 ]
Vermaelen, K. [14 ]
Frontera, O. A. [15 ]
Ready, N. [16 ]
Fontecedro, A. Curioni [17 ]
Linardou, H. [18 ]
Poddubskaya, E. [19 ]
Fischer, J. [20 ]
Iordan, I. [21 ]
Groen, H. [22 ,23 ]
Pillai, R. [24 ]
Li, S. [25 ]
Fiore, J. [25 ]
Chang, H. [25 ]
Acevedo, A. [25 ]
Paz-Ares, L. [26 ]
机构
[1] Aix Marseille Univ, Marseille, France
[2] CNRS, INSERM, Crcm, Marseille, France
[3] Aphm, Marseille, France
[4] Hop Sainte Musse, Toulon, France
[5] Vall DHebron Univ Hosp, Barcelona, Spain
[6] Oncol Inst Ion Chiricuta, Cluj Napoca, Romania
[7] Univ Med & Pharm Iuliu Hatieganu, Cluj Napoca, Romania
[8] Hop Sacre Coeur Montreal, Montreal, PQ, Canada
[9] Ist Ricovero E Cura A Carattere Sci Irccs Osped P, Lung Canc Unit, Genoa, Italy
[10] Matrahaza Univ, Matrahaza, Hungary
[11] Teaching Hosp, Matrahaza, Hungary
[12] Ctr Integre Univ Sante & Serv Soc Mauricie & Ctr, Trois Rivieres, PQ, Canada
[13] Azienda Osped Santa Maria Terni, Terni, Italy
[14] Ghent Univ Hosp, Ghent, Belgium
[15] Inst Nacl Canc, Santiago, Chile
[16] Duke Canc Ctr, Durham, NC USA
[17] Univ Hosp Zurich, Dept Med Oncol & Hematol, Zurich, Switzerland
[18] Metropolitan Hosp, Oncol Unit, Athens, Greece
[19] Vitamed Llc, Moscow, Russia
[20] Lowenstein Clin Ggmbh, Lowenstein, Germany
[21] Clin Ferdinand, Bucharest, Romania
[22] Univ Groningen, Groningen, Netherlands
[23] Univ Med Ctr Groningen, Groningen, Netherlands
[24] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[25] Bristol Myers Squibb, Princeton, NJ USA
[26] Hospt Univ 12 Octubre, Madrid, Spain
关键词
nivolumab; ipilimumab; NSCLC;
D O I
10.1016/j.jtho.2019.08.424
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OA04.02
引用
收藏
页码:S214 / S215
页数:2
相关论文
empty
未找到相关数据